EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Stereotactic radiosurgery for 1–10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial

Rami A El Shafie iD, Denise Bernhardt iD, Thomas Welzel, Annabella Schiele, Daniela Schmitt, Paul Thalmann, Sinem Erdem, Angela Paul, Simon Höne, Kristin Lang, Laila König, Fabian Weykamp und 10 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae201 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Rami A El Shafie und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Cranial Irradiation, Radiosurgery. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stereotactic radiosurgery (SRS) is an emerging alternative to whole-brain radiotherapy (WBRT) for treating multiple brain metastases (BM), reducing toxicity, and improving tumor control. The CYBER-SPACE trial compared SRS based on either SPACE or MPRAGE MRI sequence for avoiding or delaying WBRT in patients with 1–10 BM.

Methods

Patients with 1–10 untreated BM were randomized 1:1 to receive SRS of all lesions based on either SPACE or MPRAGE MRI sequences. If subsequently new BM occurred, SRS was repeated. WBRT was indicated upon occurrence of >10 new BM, leptomeningeal disease, or exhausted SRS-radiotolerance. The primary outcome was freedom from WBRT indication (WBRTi). Secondary outcomes included overall survival (OS), safety, and quality of life.

Results

A total of 202 patients were randomized; SPACE n = 99, MPRAGE n = 103. Twelve-month WBRTi-free survival was 77.1% (95% CI: 69.5%–83.1%) overall, 78.5% (95% CI: 66.7%–86.5%) for SPACE, and 76.0% (95% CI: 65.2%–83.9%) for MPRAGE (hazard ratio [HR] = 0.84, 95% CI: 0.43–1.63, P = .590). Patients with 5–10 BM had shorter WBRTi-free survival (HR = 3.13, 95% CI: 1.53–6.40, P = .002). Median OS was 13.1 months overall, 10.5 months for SPACE, and 15.2 months for MPRAGE (HR = 1.10, 95% CI: 0.78–1.56, P = .585). Neurologic death rate was 10.1%. Predictors for longer OS included Karnofsky Performance Status >80% (HR = 0.51, 95% CI: 0.33–0.77, P = .002) and concurrent immunotherapy (HR = 0.34, 95% CI: 0.23–0.52, P < .001).

Conclusions

The more sensitive SPACE sequence did not improve outcomes over MPRAGE. SRS with thorough monitoring and immediate re-treatment for new lesions decreases the need for WBRT and achieves low neurologic death rates. SRS should be considered a favorable alternative to WBRT for patients with 1–10 BM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCranial IrradiationRadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFollow-Up StudiesMagnetic Resonance ImagingPrognosisQuality of LifeSurvival RateProspective Studies

Stichwörter der Autor:innen

MRI monitoringSPACE sequencemultiple brain metastasesstereotactic radiosurgery (SRS)whole-brain radiotherapy (WBRT)

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
  • Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Department of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Department of Radiation Oncology, School of Medicine and Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
  • Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.

ORCID-Profile: Rami A El Shafie, Denise Bernhardt

Zitieren

APA

El Shafie, R. A., Bernhardt, D., Welzel, T., Schiele, A., Schmitt, D., Thalmann, P., Erdem, S., Paul, A., Höne, S., Lang, K., König, L., Weykamp, F., Adeberg, S., Lentz-Hommertgen, A., Jäkel, C., Bozorgmehr, F., Nestle, U., Thomas, M., Sander, A., …, & Rieken, S. (2025). Stereotactic radiosurgery for 1–10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae201

Vancouver

El Shafie RA, Bernhardt D, Welzel T, Schiele A, Schmitt D, Thalmann P, et al. Stereotactic radiosurgery for 1–10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae201

BibTeX
@article{ElShafie2025,
  author = {El Shafie, Rami A and Bernhardt, Denise and Welzel, Thomas and Schiele, Annabella and Schmitt, Daniela and Thalmann, Paul and Erdem, Sinem and Paul, Angela and Höne, Simon and Lang, Kristin and König, Laila and Weykamp, Fabian and Adeberg, Sebastian and Lentz-Hommertgen, Adriane and Jäkel, Cornelia and Bozorgmehr, Farastuk and Nestle, Ursula and Thomas, Michael and Sander, Anja and Kieser, Meinhard and Debus, Jürgen and Rieken, Stefan},
  title = {Stereotactic radiosurgery for 1–10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae201}
}
Kostenlos starten →